WebDoctor Encyclopedia

Chronic myeloid & MDS

Systemic mastocytosis

Systemic mastocytosis is a rare disorder in which abnormal mast cells, usually with a KIT D816V mutation, build up in the bone marrow and other organs, causing flushing, itching and anaphylaxis.

Medically reviewed Last reviewed October 21, 2026

What is systemic mastocytosis?

Systemic mastocytosis (SM) is a rare condition in which abnormal mast cells build up in the bone marrow and other organs. Mast cells are immune cells that release histamine and other chemicals during allergic reactions.

In SM, the mast cells come from a single faulty cell (they are clonal). In almost all adults, they carry a change in the KIT gene called D816V, which keeps them switched on and growing.

The extra mast cells release their chemicals too easily. This causes flushing, itching, stomach cramps, diarrhoea and, in some people, severe allergic reactions (anaphylaxis), for example after a wasp or bee sting.

Most adults have indolent systemic mastocytosis. It does not usually shorten life, but the symptoms can affect daily life a great deal. A smaller group has advanced SM, which damages organs and behaves like a blood cancer.

SM is classed by the World Health Organization as a myeloid neoplasm, in the same broad family as chronic myeloid blood cancers. Treatments range from antihistamines to targeted drugs such as avapritinib and midostaurin.

1. Key facts at a glance

Feature Details
Type of disease Clonal mast cell neoplasm (myeloid neoplasm)
How common About 1 in 10,000 people; likely under-diagnosed
Typical age Usually diagnosed at 30-60
Sex Men and women equally
Key gene change KIT D816V in over 90% of adults
Main organs Bone marrow, skin, bones, gut, liver and spleen
Key blood test Raised serum tryptase, often above 20 ng/mL
Main treatments Antihistamines and other mast cell stabilisers, adrenaline pens, bone protection, avapritinib, midostaurin, cladribine, stem cell transplant
Outlook Indolent SM: near-normal life expectancy; advanced SM: months to a few years depending on type

2. Types of mastocytosis

Type Main features Behaviour
Cutaneous mastocytosis Skin only; mostly in children Often improves or clears by adolescence
Bone marrow mastocytosis Marrow involvement without skin lesions; tryptase often lower Indolent; high risk of severe sting reactions
Indolent SM (ISM) The commonest adult form; usually with skin spots Life expectancy close to normal
Smouldering SM (SSM) High mast cell burden (“B-findings”), such as a large liver or spleen or very high tryptase Slow, but higher risk of progression
Aggressive SM (ASM) Organ damage (“C-findings”) such as low blood counts, liver dysfunction, bone destruction or malabsorption A cancer needing treatment
SM with an associated haematological neoplasm (SM-AHN) SM together with another blood cancer, often CMML or MDS Outlook mostly depends on the other blood cancer
Mast cell leukaemia (MCL) Mast cells make up 20% or more of marrow cells Very rare and aggressive
Mast cell sarcoma A solid tumour of very abnormal mast cells Extremely rare and aggressive

3. Causes and risk factors

Factor Notes
KIT D816V mutation Acquired during life in a blood stem cell; not inherited in most cases
Other mutations TET2, SRSF2, ASXL1 and RUNX1 changes are common in advanced SM and worsen the outlook
Family history Familial cases are very rare
Hereditary alpha-tryptasaemia An inherited extra copy of the tryptase gene, more common in people with SM, which may make reactions more severe

4. How does it look?

4.1 On the skin

About 80% of adults with ISM have skin lesions.

Feature What it looks like
Spots Small, round, red-brown or tan spots or slightly raised bumps, often on the thighs and trunk
Spread Many spots, usually symmetrical, sparing the face, palms and soles
Darier sign Rubbing a spot makes it red, swollen and itchy within minutes
Flushing Sudden redness of the face, neck and chest
Old name Urticaria pigmentosa; now called maculopapular cutaneous mastocytosis

4.2 Inside the body and on scans

Finding What is seen
Bones Thinning (osteoporosis), fractures of the spine, or areas of dense bone (osteosclerosis) on X-ray or DEXA scan
Liver and spleen Enlargement on ultrasound or CT, mainly in smouldering and advanced SM
Lymph nodes Swollen nodes in some people
Gut Inflammation or poor absorption in advanced disease

4.3 Under the microscope

Feature What the pathologist sees
Bone marrow Dense clusters of 15 or more mast cells, often next to blood vessels or bony trabeculae
Cell shape Spindle-shaped, atypical mast cells instead of round ones
Stains Tryptase and CD117 (KIT) positive; abnormal CD25, CD2 or CD30 expression
Genetic test Sensitive PCR shows KIT D816V

5. Symptoms

Symptoms vary a lot from person to person. Many are caused by chemicals released from mast cells, others by the build-up of cells in organs.

5.1 Mast cell mediator symptoms

Area Symptoms
Skin Itching, flushing, hives, red-brown spots that swell when rubbed
Gut Stomach cramps, nausea, heartburn, diarrhoea
Heart and circulation Fast heartbeat, light-headedness, low blood pressure and fainting
Breathing Wheezing or throat tightness during reactions
Brain Headaches, poor concentration (“brain fog”), low mood
Whole body Tiredness, bone and muscle pain
Anaphylaxis Sudden, severe reactions, often after insect stings, some drugs, anaesthetics, alcohol, heat or exercise

5.2 Common triggers

Trigger Examples
Insect stings Wasps, bees and hornets; the commonest cause of severe reactions
Physical factors Heat, sudden temperature change, friction, pressure, vigorous exercise
Medicines Some painkillers (aspirin, other NSAIDs, opioids), some anaesthetic drugs, contrast dye for X-rays
Food and drink Alcohol, spicy food and very hot drinks in some people
Emotional stress Anxiety and lack of sleep
Infections Colds and other infections can worsen symptoms

Triggers differ between people, and many people tolerate some of these without problems. Keeping a symptom diary helps identify personal triggers.

5.3 Symptoms of advanced SM

Symptom Cause
Tiredness, infections, bruising Low blood counts from marrow failure
Swollen tummy Enlarged liver or spleen, fluid in the abdomen (ascites)
Weight loss and diarrhoea Poor absorption of food
Bone pain and fractures Bone destruction
Yellow skin Liver damage

5.4 When to see a doctor

See a doctor if you have repeated flushing, unexplained hives, red-brown skin spots that itch when rubbed, or fainting after a sting. Anyone with a severe allergic reaction should get emergency help and later be tested.

6. Diagnosis

6.1 Tests

Test Why it is done
Serum tryptase Raised in most people with SM; a level above 20 ng/mL is a diagnostic criterion
Skin biopsy Confirms mastocytosis in the skin
KIT D816V test on blood A sensitive blood test that often detects the mutation
Bone marrow biopsy The key test; shows mast cell clusters, CD25 expression and the subtype
Full blood count and liver tests Look for organ damage
DEXA scan and X-rays Check bone health
Ultrasound or CT Check liver, spleen and lymph nodes
Gene panel Looks for other mutations in advanced SM

6.2 WHO diagnostic criteria

SM is diagnosed when there is one major and at least one minor criterion, or three minor criteria.

Criterion Requirement
Major Multifocal dense clusters of 15 or more mast cells in bone marrow or another organ outside the skin
Minor 1 More than 25% of mast cells are spindle-shaped or atypical
Minor 2 An activating KIT mutation, usually D816V
Minor 3 Mast cells express CD25, CD2 and/or CD30
Minor 4 Serum tryptase persistently above 20 ng/mL (adjusted if hereditary alpha-tryptasaemia is present)

6.3 Mastocytosis and mast cell activation syndrome

Mast cell activation syndrome (MCAS) is a related but different diagnosis. In MCAS, people have repeated episodes of mast cell symptoms with a measurable rise in tryptase during attacks, and the symptoms improve with mast cell medicines.

Systemic mastocytosis is one cause of MCAS, but MCAS can also happen with normal, non-clonal mast cells, for example in people with severe allergies. A bone marrow test separates the two.

7. Treatment

7.1 Symptom control for all types

Treatment Purpose
H1 antihistamines (for example cetirizine, fexofenadine) Itching, flushing, hives
H2 blockers (for example famotidine) Stomach pain, acid and diarrhoea
Oral cromolyn sodium Gut symptoms
Leukotriene blockers (montelukast) Additional symptom control
Omalizumab Repeated anaphylaxis despite other treatment
Adrenaline auto-injectors Carry two at all times for anaphylaxis
Venom immunotherapy Lifelong, for people who have reacted to insect stings
Bone protection Calcium, vitamin D, bisphosphonates or denosumab
Trigger avoidance Heat, friction, alcohol and some drugs; tell anaesthetists before operations

7.2 Disease-directed treatment

Drugs that act on the abnormal mast cells themselves are used for advanced SM, and for indolent SM when symptoms stay severe despite the medicines above. Avapritinib was approved for indolent SM in 2023, after a placebo-controlled trial showed better symptom scores and large falls in tryptase.

Treatment Who it is for Notes
Avapritinib ISM with moderate-severe symptoms (low dose); advanced SM (higher dose) Targets KIT D816V; reduces symptoms, tryptase and mast cells
Midostaurin Advanced SM Multi-kinase inhibitor; responses in about 60%
Cladribine Advanced SM, or ISM with severe symptoms Chemotherapy given in short courses
Interferon alfa Selected patients, including bone disease Older option with more side effects
Treatment of the associated cancer SM-AHN For example azacitidine for CMML or MDS
Allogeneic stem cell transplant Fit patients with advanced SM The only potentially curative option

8. Side effects of treatment

Treatment Possible effects
Antihistamines Drowsiness with older types
Avapritinib Swelling around the eyes, memory problems, low blood counts, rare bleeding in the brain (mainly at higher doses and low platelets)
Midostaurin Nausea, vomiting, diarrhoea
Cladribine Low blood counts, infections
Stem cell transplant Serious infections and graft-versus-host disease

9. Outlook

Type Approximate median survival
Indolent and bone marrow SM Close to normal life expectancy; progression in under 5%
Smouldering SM Several years to decades, but shorter than indolent SM
Aggressive SM About 3-4 years historically, likely improving with new drugs
SM-AHN About 2 years, depending on the associated cancer
Mast cell leukaemia Months historically; better with modern targeted drugs and transplant

10. Living with systemic mastocytosis

Many people with ISM live full lives once symptoms are controlled. Key steps include:

  • Carrying two adrenaline pens and an emergency card or bracelet
  • Knowing and avoiding personal triggers
  • Telling surgeons, dentists and anaesthetists before procedures
  • Having regular bone density scans
  • Having blood tests, including tryptase, about once a year, or more often in advanced SM

Specialist mastocytosis centres, often linked to the European Competence Network on Mastocytosis, offer coordinated care from haematologists, dermatologists and allergists.

11. Frequently asked questions

Question Answer
Is mastocytosis an allergy? No, but mast cells react too easily, so allergy-like symptoms are common
Is it cancer? It is classed as a myeloid neoplasm. Indolent SM behaves more like a long-term condition; advanced SM is treated like a blood cancer
Will my children get it? Very unlikely; it is usually not inherited
Can I have an operation? Yes, with planning; anaesthetists give premedication and avoid trigger drugs
Can I drink alcohol? Some people can; others find it triggers flushing and should avoid it

12. Questions to ask your care team

  • Which type of mastocytosis do I have, and what is my tryptase level?
  • Should I carry adrenaline pens, and how many?
  • Do I need venom immunotherapy?
  • How often should my bones be checked?
  • Would avapritinib or another targeted drug help my symptoms?
  • What should I tell my dentist, surgeon or anaesthetist?

Resources

  1. Valent, P. et al. (2021) ‘Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal’, HemaSphere, 5(11), e646.
  2. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  3. Lim, K.H. et al. (2009) ‘Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors’, Blood, 113(23), pp. 5727-5736.
  4. Pardanani, A. (2023) ‘Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management’, American Journal of Hematology, 98(7), pp. 1097-1116.
  5. Gotlib, J. et al. (2016) ‘Efficacy and safety of midostaurin in advanced systemic mastocytosis’, New England Journal of Medicine, 374(26), pp. 2530-2541.
  6. Gotlib, J. et al. (2021) ‘Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial’, Nature Medicine, 27(12), pp. 2192-2199.
  7. Gotlib, J. et al. (2023) ‘Avapritinib versus placebo in indolent systemic mastocytosis’, NEJM Evidence, 2(6), EVIDoa2200339.
  8. Valent, P. et al. (2014) ‘Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis’, Allergy, 69(10), pp. 1267-1274.

Prepared by the editorial team, October 2026.